



# Best practice in comprehensive abortion care

Best Practice Paper No. 2  
June 2015

Published by the Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London NW1 4RG

[www.rcog.org.uk](http://www.rcog.org.uk)

Registered charity no. 213280

First published 2015

© 2015 The Royal College of Obstetricians and Gynaecologists

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [[www.cla.co.uk](http://www.cla.co.uk)]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

Copy-editing and typesetting: Andrew Welsh ([www.andrew-welsh.com](http://www.andrew-welsh.com))

## Contents

Introduction to the <i>Best Practice Papers</i>	ii
Introduction	1
Information for women requesting abortion	1
Information for staff assessing women prior to induced abortion	3
Taking the medical history	3
Blood tests	3
Determining gestational age	4
STI screening	4
Prevention of infective complications	4
Contraception	4
Information for staff providing the abortion	5
For pregnancies of less than 14 weeks of gestation	5
For pregnancies of 14 weeks of gestation or more	6
Cervical preparation before surgical abortion	6
Medication for pain management	6
Contraceptive provision	7
Information for staff concerned with care after induced abortion	7
Information to provide	7
Contraception	7
Anti-D IgG	8
Management of incomplete abortion	8
Assessment	8
Management	9
Service delivery	10
Access to services	10
Information provision	11
Initial assessment	11
Arrangements for the procedure	11
Evidence sources	12
Additional literature reviewed	12
Appendix: Post-abortion contraception	13

## Introduction to the *Best Practice Papers*

Professionals providing reproductive health care have a responsibility to ensure that the women and men they treat benefit from the latest evidence-based clinical practices. In support of these, and in line with the Royal College of Obstetricians and Gynaecologists' mandate of improving health care for women everywhere, by setting standards for clinical practice, this Best Practice Paper sets out the essential elements of a high-quality abortion care service including comprehensive post-abortion care and contraception.

The best practices described are drawn from current evidence-based guidance produced by organisations such as the World Health Organization (WHO), the Royal College of Obstetricians and Gynaecologists, and Ipas. So as to be readable and useful to people providing healthcare on a daily basis, the paper has been deliberately kept short and succinct. Therefore the primary evidence for the recommendations and the strength of that evidence has been omitted but can be found in the original source documents. Very recently published evidence has been assessed to determine whether any of the recommendations from current guidelines should be amended.

Recognising that different healthcare providers may be involved at different stages of the management of induced abortion, the paper has been divided into sections specific to these stages where appropriate.

The use of the clinical recommendations should be individualised to each woman, with emphasis on her clinical needs.

The recommendations may also be used as a tool to assist policy makers in moving their services forward.

While the paper may be used for reference in any country, varying legal, regulatory, policy and service-delivery contexts may require some recommendations to be adapted to the local context; however, it is important to ensure that best practice is maintained.

For support on adapting the document while still maintaining good practice, please write to [leadingsafechoices@rcog.org.uk](mailto:leadingsafechoices@rcog.org.uk).

## Acknowledgements

This document was developed by Anna Glasier in close consultation with David Baird, Paul Blumenthal, Sharon Cameron, Alison Fiander, Ailsa Gebbie, Stefan Gebhardt, Natalie Kapp, Hawa Kawawa, Judy Kluge, Patricia Lohr, Grace Magembe, Gileard Masenga, Projestine Muganyizi, Malika Patel, Gregory Petro, Lesley Regan, Sam Rowlands, Petrus Steyn and Zephne van der Spuy. It was peer reviewed by Kelly Culwell, Kristina Gemzell-Danielsson and Angela Hyde.

## The Leading Safe Choices initiative

Globally, 222 million women would like to prevent or delay pregnancy but have no access to contraception. Meeting this need would allow women to control their own fertility and reduce maternal deaths by one-third, with lasting benefits for their families and communities.

Thanks to a three year, multi-million pound grant, an important new initiative called Leading Safe Choices offers the RCOG a unique opportunity to address this unmet need. Leading Safe Choices will initially pilot in Tanzania and South Africa and focus on postpartum family planning (PPFP) in both countries, and on comprehensive abortion care in South Africa and comprehensive post-abortion care in Tanzania.

The initiative will take an integrated systems approach, working within existing health structures and with professionals currently working in women's health in these two countries. The pilot phase will focus on selected high-volume maternity hospitals and midwifery units, increasing skills and improving quality in PPFP and comprehensive abortion care.

The programme has three broad objectives:

- 1 developing RCOG *Best Practice Papers* on PPFP and comprehensive abortion care in South Africa and on comprehensive post-abortion care in Tanzania
- 2 training healthcare providers and supporting the delivery of high-quality PPFP and comprehensive abortion care in South Africa and comprehensive post-abortion care in Tanzania
- 3 establishing a formal accreditation and certification process to:
  - recognise competence
  - raise standing within professions
  - increase the uptake and quality of service provision.

The long-term vision is to expand the Initiative across South Africa and Tanzania and to other countries, following on from this pilot phase.

## Introduction

Each year, 22 million unsafe abortions are estimated to take place, resulting in the death of approximately 47 000 women. Some 5 million women suffer injury as a result of complications due to unsafe abortion, often leading to chronic disability. Abortion need **not** be unsafe. Safe abortion should be and can be available and accessible for all women, to the full extent that the law allows. Even in countries where legal abortion is severely restricted, in circumstances where it is permitted, such as to save the life of the woman, it should always be done safely.

Abortion is not a complex procedure. A range of providers, including nurses and midwives, have been shown to be competent to deliver abortion services safely in a number of settings. As with many other medical procedures, adherence to best practice standards will ensure that the most effective and the safest services are delivered. This *Best Practice Paper* is designed to be used on a daily basis by healthcare workers who are responsible for delivering pre-abortion counselling and assessment, and abortion and post-abortion care services including post-abortion contraception.

All aspects of abortion care should be delivered in a respectful and sensitive manner that recognises women as decision makers.

## Information for women requesting abortion

Women should be informed about their pregnancy options so that they can make an informed choice about their preferred course of action.

All women who require more support in deciding whether to continue the pregnancy or have an abortion should be identified and offered further opportunities to discuss their decision.

If performed in line with best practice, abortion is safer than childbirth.

The following information should be provided to women requesting abortion, with an emphasis on the overall safety of the procedure and in a way that women can understand:

- the choice of abortion method available (if appropriate) and the characteristics of each (see Table 1)
- the side effects, risks and complications associated with each available abortion method
- what will be done during and after the abortion
- symptoms likely to be experienced both during and after the abortion (e.g. menstrual-like cramps, pain and bleeding)
- how long it will take for the abortion to be completed
- what pain management will be made available
- follow-up care, including contraceptive advice and provision
- the range of emotions commonly experienced after having an abortion
- other services that are available, such as sexually transmitted infection (STI) testing and support for women experiencing sexual coercion or domestic violence.

**Table 1** Characteristics of abortion procedures; adapted from WHO (2014) *Clinical Practice Handbook for Safe Abortion*

Medical abortion	Surgical abortion
<ul style="list-style-type: none"> <li>• avoids surgery</li> <li>• mimics miscarriage</li> <li>• controlled by the woman and may take place at home (at less than 9 weeks of pregnancy)</li> <li>• takes time (hours to days) to complete abortion, and the timing may not be predictable</li> <li>• women experience bleeding and cramping, and potentially some other side effects (nausea, vomiting)</li> <li>• may require more clinic visits than surgical abortion</li> </ul> <p><i>May be necessary in the following situations:</i></p> <ul style="list-style-type: none"> <li>• for severely obese women</li> <li>• if the woman has uterine malformations or fibroids, or has had previous cervical surgery</li> <li>• if the woman wants to avoid surgical intervention</li> <li>• if a pelvic examination is not feasible or is unwanted</li> </ul>	<ul style="list-style-type: none"> <li>• quick procedure</li> <li>• complete abortion is easily verified by evaluation of aspirated products of conception</li> <li>• takes place in a healthcare facility</li> <li>• sterilisation of the woman or placement of an intrauterine device (IUD) may be performed at the same time as the procedure</li> <li>• requires instrumentation of the uterus</li> <li>• small risk of uterine or cervical injury</li> <li>• timing of abortion is controlled by the facility and provider</li> </ul> <p><i>May be necessary in the following situations:</i></p> <ul style="list-style-type: none"> <li>• if there are contraindications to medical abortion</li> <li>• if there are constraints for the timing of the abortion</li> </ul>

The information should be given in a non-judgemental and supportive way.

This is particularly important for adolescent girls who may be visiting a reproductive health facility for the first time. If the law requires an adult to consent to her procedure, this should be clearly explained at the start of the consultation. While all young people should be encouraged to involve a trusted adult in their decision if possible, do **not** insist on parents' authorisation unless it is a legal requirement.

The **pre-abortion consultation** should confirm the woman's decision and should include the following information:

- 1 Abortion is a safe procedure for which major complications and mortality are rare at all gestations. If performed in line with best practice, abortion is safer than childbirth.
- 2 The earlier in pregnancy an abortion is undertaken, the safer it is likely to be.
- 3 Surgical and medical methods of abortion carry a small risk of failure to end the pregnancy (1 or 2 per 100 procedures).
- 4 There is a small risk (less than 2 in 100 for surgical and 5 in 100 for medical) of the need for further intervention to complete the procedure, i.e. surgical intervention following medical abortion or re-evacuation following surgical abortion.
- 5 The following complications may occur:
  - severe bleeding requiring transfusion – the risk is lower for first-trimester abortions (less than 1 in 1000), rising to around 4 in 1000 at gestations beyond 20 weeks
  - uterine rupture in association with second-trimester medical abortion – the risk is less than 1 in 1000.

*For surgical abortions only:*

- cervical trauma – the risk of damage is no more than 1 in 100 and is lower for first-trimester abortions; trauma is less likely if cervical preparation is undertaken in line with best practice
  - uterine perforation – the risk is in the order of 1–4 in 1000 and is lower for first-trimester abortions.
- 6 Further treatment (e.g. blood transfusion, laparoscopy, laparotomy or hysterectomy) may be required, should one of these complications occur.
- 7 Upper genital tract infection of varying degrees of severity is unlikely, but may occur after medical or surgical abortion and is usually associated with pre-existing infection.

There are a number of myths about the consequences of abortion. If the woman expresses concern, she can be reassured that there are no proven associations between induced abortion and subsequent ectopic pregnancy, placenta praevia, infertility, breast cancer or psychological problems.

It is best practice to discuss contraception at the initial consultation.

The benefits of the most effective methods (IUDs and implants) should be explained.

If a contraceptive method is chosen, that choice should be documented so that it can be provided when the abortion is undertaken.

## Information for staff assessing women prior to induced abortion

It should be confirmed that the woman is seeking abortion voluntarily. Those responsible for assessing women in respect of medical eligibility for abortion should be able to ensure that women who need specialist care (e.g. women with serious chronic medical conditions such as heart disease) are referred as soon as possible to an appropriate service.

It is important at this stage to make sure that abortion eligibility by gestation is correctly assessed and that any ongoing genital tract infection is excluded or properly managed.

## Taking the medical history

It should be determined whether the woman is eligible to undergo abortion safely in the service concerned by taking a general medical history to exclude serious or relevant acute or chronic medical conditions.

### *Blood tests*

Pre-abortion assessment should include determination of Rhesus blood status if testing is available.

Where clinically indicated, pre-abortion assessment may also include measurement of haemoglobin concentration.

## Determining gestational age

It is not necessary to determine the exact gestational age but rather to make sure that the gestation falls within the range of eligibility for a particular method of inducing abortion. The date of onset of the last menstrual period, bimanual pelvic examination, abdominal examination and recognition of symptoms of pregnancy are usually adequate after a positive pregnancy test. Table 2 shows gestation in both weeks and days of amenorrhoea.

**Table 2** Weeks of gestation in terms of days since the last menstrual period (LMP); reproduced from RCOG (2011) *The Care of Women Requesting Induced Abortion*, Evidence-based Clinical Guideline Number 7

Completed weeks	0	1	2	3	4	5	6	7	8	9	10	11	12
Days since LMP	0–6	7–13	14–20	21–27	28–34	35–41	42–48	49–55	56–62	63–69	70–76	77–83	84–90

Completed weeks	13	14	15	16	17	18	19	20	21	22	23	24
Days since LMP	91–97	98–104	105–111	112–118	119–125	126–132	133–139	140–146	147–153	154–160	161–167	168–174

Routine pre-abortion ultrasound scanning is unnecessary but, if available, may be useful if there are concerns about complications such as ectopic pregnancy.

## STI screening

It is best practice to undertake a risk assessment for STIs for all women (e.g. HIV, chlamydia, gonorrhoea, syphilis), and then to screen for them if appropriate and available. This should be done without delaying the abortion. The partners of women who test positive for STIs should be informed and advised about treatment, provided that the woman gives her consent to this.

Ideally, a system for partner notification and follow-up or referral should be in place.

Services should make available information about the prevention of STIs, and offer condoms for STI prevention to all women undergoing abortion.

## Prevention of infective complications

Routine use of antibiotics at the time of surgical abortion is best practice as it reduces the risk of infection after the abortion. However, abortion should not be delayed if antibiotics are not available.

The following regimens are recommended for perisurgical abortion antibiotic **prophylaxis**:

- 200 mg doxycycline within 2 hours before the procedure

**OR**

- 500 mg azithromycin within 2 hours before the procedure.

## Contraception

Effective methods of contraception should be discussed with women at the initial assessment and a plan agreed, and documented, for contraception after the abortion. Women should be advised of the greater effectiveness of long-acting reversible methods of contraception (LARC: implants and



IUDs) and encouraged (but not coerced) to choose them. Immediately after surgical abortion is an optimal time for insertion of an IUD (and is safe after both first- and second-trimester surgical abortions). Contraceptive implants can be provided at any time once the abortion procedure has started.

## Information for staff providing the abortion

The most appropriate abortion methods/regimens (surgical or medical) should be determined and discussed with the woman (see Table 1).

Dilatation and sharp curettage (D&C) is an obsolete method of surgical abortion, for which the current recommended method is vacuum aspiration.

### *For pregnancies of less than 14 weeks of gestation*

#### **Surgical abortion**

Either manual or electric vacuum aspiration:

- There is no lower limit of gestation for surgical abortion.
- It is best practice to inspect aspirated tissue at all gestations to confirm complete evacuation; this is essential following vacuum aspiration at under 7 weeks of gestation.
- During vacuum aspiration, the uterus should be emptied using the suction cannula and forceps (if required) only. The procedure should **not** be routinely completed by sharp curettage.
- Use of medications containing either oxytocin or ergometrine are **not** recommended for prophylaxis to prevent excessive bleeding either at the time of vacuum aspiration or afterwards.
- Sharp curettage should not be performed.

**OR**

#### **Medical abortion**

If mifepristone is available, it is best practice to use it in combination with misoprostol as it shortens the induction–abortion interval, reduces side effects and decreases the rate of ongoing pregnancy.

Effective regimens for medical abortion include:

- at up to 63 days of gestation, mifepristone 200 mg orally, followed 24–48 hours later by misoprostol 800 micrograms given by the vaginal, buccal or sublingual route; if misoprostol is provided for a woman to use at home, a single dose of 800 micrograms should be provided
- from 64 days to 13 weeks and 6 days, mifepristone 200 mg orally, followed 24–48 hours later by misoprostol 800 micrograms given by the vaginal, buccal or sublingual route, followed by misoprostol 400 micrograms every 3 hours until abortion occurs

**OR**

- If mifepristone is not available, and for all gestations up to 13 weeks and 6 days, misoprostol 800 micrograms given by the vaginal, buccal or sublingual route, followed by misoprostol 400 micrograms every 3 hours until abortion occurs.

## *For pregnancies of 14 weeks of gestation or more*

### **Surgical abortion**

Surgical abortion can be performed by trained providers using:

- vacuum aspiration using large bore cannulae
- dilatation and evacuation (D&E).

**OR**

### **Medical abortion**

At 14 weeks of gestation or more, medical abortion should be undertaken in a medical facility. If mifepristone is available, it should be used in combination with misoprostol as it shortens the induction–abortion interval, reduces side effects and decreases the rate of ongoing pregnancy. The regimens are as follows:

- mifepristone 200 mg orally, followed 12–48 hours later by misoprostol 800 micrograms vaginally, followed by misoprostol 400 micrograms orally or vaginally every 3 hours until abortion occurs; if after 24 hours abortion does not occur, mifepristone can be repeated 3 hours after the last dose of misoprostol, and 12 hours later misoprostol may be recommenced

**OR**

- where mifepristone is not available, misoprostol 800 micrograms followed by misoprostol 400 micrograms every 3 hours until abortion occurs.

### *Cervical preparation before surgical abortion*

Cervical preparation should be used for all women with a pregnancy of gestational age over 14 weeks. Suitable preparations include:

- osmotic dilators 12–24 hours before the procedure; if the pregnancy is at less than 18 weeks of gestation, osmotic dilators will be effective at just 3–4 hours before the procedure

**OR**

- mifepristone 200 mg 12–24 hours before the procedure

**OR**

- misoprostol 400 micrograms vaginally 3 hours or sublingually 2 hours before the procedure.

Cervical preparation may be considered for women before 14 weeks if there is a high risk for cervical injury or uterine perforation. The following regimen is recommended:

- Misoprostol 400 micrograms administered vaginally 3 hours before the procedure or sublingually 2 hours before the procedure.

### *Medication for pain management*

For both medical and surgical abortions, analgesia (pain relief) should **always** be offered and provided without delay, if requested.

- In most cases, analgesics (e.g. nonsteroidal anti-inflammatory drugs (NSAIDs)), local anaesthesia and/or conscious sedation supplemented by verbal reassurance are sufficient.

- The need for pain management increases with gestational age and narcotic analgesia may be required.
- Prophylactic NSAIDs at the time of initiation of misoprostol for second-trimester medical abortion may reduce the need for narcotic analgesia.
- Prophylactic paracetamol (oral or rectal) is ineffective in reducing pain after surgical abortion.

**Local anaesthesia**, such as lidocaine, can be used to alleviate discomfort from mechanical cervical dilatation and uterine evacuation during surgical abortion.

General anaesthesia is not recommended for routine abortion procedures, as it has been associated with higher rates of complications than analgesia and local anaesthesia.

### *Contraceptive provision*

If a woman has chosen a contraceptive method that can be provided as part of or during the abortion procedure (e.g. IUD insertion once manual vacuum aspiration is completed), it should be ensured that this is done. IUDs can be inserted at the time of the abortion in both the first and second trimesters. Contraceptive implants can be inserted at any time during the abortion procedure.

## **Information for staff concerned with care after induced abortion**

Healthcare staff involved in post-abortion care should ensure that the woman leaves the abortion service knowing what to expect following the procedure and where to get help if necessary. They should also ensure that every woman is able to leave with a method of contraception that she can start immediately. Women should be informed of the superior effectiveness of IUDs and implants in preventing unintended pregnancy.

### *Information to provide*

Before leaving the facility, women should receive instructions about how to care for themselves after they go home, including:

- how much bleeding to expect in the next few days and weeks
- how to recognise potential complications, including signs of ongoing pregnancy
- when they can resume normal activities (including sexual intercourse)
- how and where to seek help if required.

### *Contraception*

Before they leave the healthcare facility, all women should receive contraceptive information and, if desired, the contraceptive method of their choice. If the chosen method is not available, they should be referred to a service where the method can be provided.

Women should be advised of the greater effectiveness and duration of LARC methods (implants and IUDs) and of their safety, and healthcare staff should dispel any myths there may be about these methods.

Sterilisation can be safely performed at the time of induced abortion although it can be more likely than interval sterilisation to be associated with regret.

## Anti-D IgG

If available, anti-D IgG should be given intramuscularly to all non-sensitised RhD-negative women within 72 hours following abortion.

## Management of incomplete abortion

Post-abortion care can reduce the morbidity and mortality associated with complications of either miscarriage or incomplete abortion (including abortion that was performed unsafely). Options for management for incomplete abortion include surgical and medical methods of uterine evacuation.

For women who wish to avoid another pregnancy, contraception should be discussed and a method provided. Women experiencing a miscarriage who wish to get pregnant again should be advised to wait until after having at least one normal menstrual period, longer if chronic health problems (e.g. anaemia) require treatment.

## Assessment

Incomplete abortion should be suspected when any woman of reproductive age presents with vaginal bleeding and/or abdominal pain after one or more missed menstrual periods. Ectopic pregnancy should be suspected if the uterus is small, the cervix closed and/or there is an adnexal mass.

## Unsafe abortion

In many settings it is important to distinguish between safe and unsafe abortion since the latter is much more likely to be associated with infection. Indications that an abortion has been attempted by unsafe methods include the presence of:

- vaginal laceration
- cervical injury
- uterine enlargement equivalent to a pregnancy of more than 12 weeks of gestation
- products of conception visible at the cervix.

## Infection

It is vital to identify women who may have an infection and to manage this urgently. Infection is much more likely, and much more likely to be severe, if the abortion has been performed unsafely. Clinical features suggestive of infection include:

- temperature above 37.5 °C
- localised or general abdominal tenderness, guarding and rebound
- foul odour or pus visible in the cervical os
- uterine tenderness.

Features suggestive of sepsis and indicating the need for urgent intervention include:

- hypotension
- tachycardia
- increased respiratory rate.

## Management

### If there is no suspicion of infection and uterine size is less than 14 weeks

- uterine evacuation with vacuum aspiration:
  - antibiotic prophylaxis should be given before surgical evacuation – 200 mg doxycycline within 2 hours before the procedure or a single dose of 500 mg azithromycin within 2 hours before the procedure (NB. If antibiotics are not available, the procedure should not be delayed.)

#### OR

- misoprostol 600 micrograms orally or 400 micrograms sublingually.

### If there is no suspicion of infection and uterine size is 14 weeks or larger

- evacuation using vacuum aspiration and blunt forceps if necessary:
  - antibiotic prophylaxis should be given before surgical evacuation – 200 mg doxycycline within 2 hours before the procedure (with or without 200 mg doxycycline after the abortion) or a single dose of 500 mg azithromycin within 2 hours before the procedure (NB. If antibiotics are not available, the procedure should not be delayed.)

#### OR

- misoprostol:
  - 14–28 weeks: at least 200 micrograms administered vaginally, sublingually or buccally at least 6-hourly:
    - If available and time permitting, mifepristone 200 mg orally should be administered 12–48 hours before misoprostol
    - In order to align protocols, services may use the same dosing and intervals as recommended in regimens for induced abortion
  - 28+ weeks: 25 micrograms vaginally 6-hourly or 25 micrograms orally 2-hourly.

### If infection is present the uterus should be evacuated urgently

- start broad-spectrum antibiotics immediately – intravenously if infection is severe
- transfer to a unit with the facilities for undertaking surgical evacuation if it cannot be done in the facility to which the woman presents
- if the woman is in septic shock, she should be transferred immediately to a specialist unit for surgical uterine evacuation – broad-spectrum antibiotics (such as a combination of ampicillin 0.5–1 g 6-hourly, metronidazole 500 mg 8-hourly and gentamicin 120 mg daily) should be administered intravenously prior to transfer if available
- if the skills necessary for urgent surgical uterine evacuation are not available, misoprostol can be used:
  - 14–28 weeks: At least 200 micrograms administered vaginally, sublingually or buccally at least 6-hourly
  - 28+ weeks: 25 micrograms vaginally 6-hourly or 25 micrograms orally 2-hourly.

## Information to provide after the abortion

Before leaving the facility, women should receive instructions about how to care for themselves after they go home, including:

- how much bleeding to expect in the next few days and weeks
- how to recognise potential complications, including signs of ongoing pregnancy
- when they can resume normal activities (including sexual intercourse)
- how and where to seek help if required
- women who want to try again to conceive should be advised to wait until after having at least one normal menstrual period, longer if chronic health problems (e.g. anaemia) require treatment.

## Contraception

Before they leave the healthcare facility, all women should receive contraceptive information and, if desired, the contraceptive method of their choice. If the chosen method is not available, they should be referred to a service where the method can be provided.

Women should be advised of the greater effectiveness and duration of LARC methods (implants and IUDs) and of their safety, and healthcare staff should dispel any myths that exist about these methods.

IUD insertion or female sterilisation should be delayed until the woman's health is restored and any infection is resolved. Interim contraception should be provided using the most effective acceptable method until an IUD can be inserted or sterilisation performed.

## Anti-D IgG

If available, anti-D IgG should be given intramuscularly to all non-sensitised RhD-negative women within 72 hours following abortion.

## Service delivery

The provision of a safe and effective comprehensive abortion care service depends on everyone involved in the service ensuring that everything can be done to meet the essential standards for safe abortion care. It is not enough for doctors, nurses and midwives to perform effectively if the facilities and tools that they need are not reliably available and if the service is not organised in a way that ensures safe and effective comprehensive abortion care. **Best practices for service delivery** are listed below.

### Access to services

- 1 Abortion services must be available to the fullest extent that the law allows. Healthcare providers should know what the law *does* allow in their country and be clear about the circumstances for which abortion is legal.
- 2 If a woman requesting abortion fulfils the legal criteria, there should be no further restriction of access on grounds such as age, marital status or the number of previous abortions.
- 3 Abortion is safer the sooner it is done. Services should be able to meet the local demand for abortion so that women can have their abortion at the earliest possible gestation and as close to home as possible.

- 4 As the equipment needed for routine early medical abortion is not sophisticated, this service can be provided in basic facilities, thereby increasing access to safe abortion care and enhancing convenience to women.
- 5 As the equipment and space required for a safe abortion service are similar to those needed for routine women's healthcare and family planning services, efforts should be made to provide safe abortion services in a wide range of health facilities and in an integrated manner.
- 6 All healthcare providers should be trained to provide comprehensive abortion care in line with their skills and licences. This can help spread the workload and improve the skills of *all* providers of women's health care, thereby enhancing access to and increasing the safety of abortion care.
- 7 Integrating abortion services within overall maternal/women's health care minimises the stigma associated with abortion care for both women and providers.
- 8 Where abortion services are provided but there is no provision for emergency or specialist care, there must be robust and timely pathways for referral.

### *Information provision*

- 1 There should be local arrangements in place for providing information to women and healthcare professionals on routes of access to safe abortion care.
- 2 Services should ensure that written, objective, evidence-guided information is available in a way that is understandable to women considering abortion. Information should be available in a variety of languages and formats.
- 3 Women should have access to objective information and, if required, counselling and decision-making support about their pregnancy options.
- 4 Information for women and providers should emphasise the need for confidentiality.

### *Initial assessment*

- 1 There should be a pathway to appropriate medical care for women with known significant medical conditions requiring specialist abortion care (e.g. heart disease).
- 2 Women presenting for induced abortion who are found to have a non-viable pregnancy also require contraception and sexual health care.
- 3 Women requesting abortion but who subsequently decide to continue the pregnancy should be referred for antenatal care (together with all their relevant information, such as ultrasound scan reports)
- 4 Services should identify issues/characteristics that make women particularly vulnerable (e.g. adolescents, victims of domestic abuse or gender-based violence) and refer/signpost them on to appropriate support services.

### *Arrangements for the procedure*

- 1 To minimise delay, service arrangements should be such that the abortion can be provided as soon as possible, ideally on the same day as the assessment.
- 2 A system should be in place to ensure that the required legal documentation is completed accurately and in a timely manner.
- 3 The setting for the abortion service (the consultation room, the procedure room and the recovery room) should respect the need for women's privacy and dignity.



## Evidence sources

World Health Organization. *Safe Abortion: Technical and Policy Guidance for Health Systems*. 2nd ed. Geneva: WHO; 2012 [[www.who.int/reproductivehealth/publications/unsafe\\_abortion/9789241548434/en/](http://www.who.int/reproductivehealth/publications/unsafe_abortion/9789241548434/en/)].

World Health Organization. *Clinical Practice Handbook for Safe Abortion*. Geneva: WHO; 2014 [[www.who.int/reproductivehealth/publications/unsafe\\_abortion/clinical-practice-safe-abortion/en/](http://www.who.int/reproductivehealth/publications/unsafe_abortion/clinical-practice-safe-abortion/en/)].

Royal College of Obstetricians and Gynaecologists. *The Care of Women Requesting Induced Abortion*. Evidence-based Guideline Number 7. London: RCOG; 2011 [[www.rcog.org.uk/en/guidelines-research-services/guidelines/the-care-of-women-requesting-induced-abortion/](http://www.rcog.org.uk/en/guidelines-research-services/guidelines/the-care-of-women-requesting-induced-abortion/)].

## Additional literature reviewed

Berghella V, Airoidi J, O'Neill A, Einhorn K, Hoffman M. Misoprostol for second trimester pregnancy termination in women with prior caesarean: a systematic review. *BJOG* 2009;116:1151–7.

Conde-Agudelo A, Belizan JM, Berman R, Brockman SC, Rosas-Bermudez A. Effect of the interpregnancy interval after an abortion on maternal and perinatal health in Latin America. *Int J Gynaecol Obstet* 2005;89 Suppl 1:S34–40.

Gomez Ponce de Leon R, Wing D, Fiala C. Misoprostol for intrauterine fetal death. *Int J Gynaecol Obstet* 2007;99 Suppl 2:S190–3.

Goyal V. Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review. *Obstet Gynecol* 2009;113:1117–23.

Love ER, Bhattacharya S, Smith NC, Bhattacharya S. Effect of interpregnancy interval on outcomes of pregnancy after miscarriage: retrospective analysis of hospital episode statistics in Scotland. *BMJ* 2010;341:c3967.

Mark AG, Edelman A, Borgatta L. Second-trimester postabortion care for ruptured membranes, fetal demise, and incomplete abortion. *Int J Gynaecol Obstet* 2015;129:98–103.

Passini R Jr, Cecatti JG, Lajos JG, Tedesco RP, Nomura ML, Dias TZ, et al., for the Brazilian Multicentre Study on Preterm Birth study group. Brazilian Multicentre Study on Preterm Birth (EMIP): prevalence and factors associated with spontaneous preterm birth. *PLoS One* 2014;9:e109069.

World Health Organization. *Report of a WHO Technical Consultation on Birth Spacing*. Geneva: WHO; 2005 [[www.who.int/maternal\\_child\\_adolescent/documents/birth\\_spacing05/en/](http://www.who.int/maternal_child_adolescent/documents/birth_spacing05/en/)].



## Appendix: Post-abortion contraception

(Adapted from World Health Organization (2014) *Clinical Practice Handbook for Safe Abortion*)

Generally, almost all methods of contraception can be initiated immediately following a surgical or medical abortion. Immediate start of contraception after surgical abortion refers to the same day as the procedure, and for medical abortion refers to the day the first pill of a medical abortion regimen is taken. As with the initiation of any method of contraception, the woman's medical eligibility for a method should be verified.

### Post-abortion medical eligibility recommendations for hormonal contraceptives, intrauterine devices and barrier contraceptive methods

POST-ABORTION CONDITION	FIRST TRIMESTER	SECOND TRIMESTER	IMMEDIATE POST-SEPTIC ABORTION
COC	1	1	1
CIC	1	1	1
Patch & vaginal ring	1	1	1
POP	1	1	1
DMPA, NET-EN	1	1	1
LNG/ENG implants	1	1	1
Copper-bearing IUD	1	2	4
LNG-releasing IUD	1	2	4
Condom	1	1	1
Spermicide	1	1	1
Diaphragm	1	1	1

CIC, combined injectable contraceptive; COC, combined oral contraceptive; DMPA/NET-EN, progestogen-only injectables: depot medroxyprogesterone acetate/norethisterone enantate; IUD, intrauterine device; LNG/ENG, progestogen-only implants: levonorgestrel/etonorgestrel; POP, progestogen-only pill.

#### Definition of categories

- **1:** a condition for which there is no restriction for the use of the contraceptive method.
- **2:** a condition where the advantages of using the method generally outweigh the theoretical or proven risks.
- **3:** a condition where the theoretical or proven risks usually outweigh the advantages of using the method.
- **4:** a condition that represents an unacceptable health risk if the contraceptive method is used.

### Contraception for women on antiretroviral therapy for HIV

There are potential drug interactions between some antiretroviral drugs and hormonal contraception. However, WHO has reviewed the data and concluded that the benefits of using hormonal contraception outweigh the risks (2015 MEC, Category 2).